Form 4 Bicara Therapeutics Inc. For: Sep 08 Filed by: Cohlhepp Ryan

Thu, 10 Sep 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260910/27048750.html

Cantor Fitzgerald Reiterates Overweight Rating on Bicara Therapeutics Inc (BCAX)

Thu, 10 Sep 2026 09:27:00 -0400

Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Bicara Therapeutics Inc (NASDAQ: BCAX).

The analyst commented, "We continue to believe that BCAX shares remain meaningfully undervalued given ficerafusp’s potential to address the large and underserved HPV-negative HNSCC market. The company’s $1B EV is wellbelow the $8B GMAB (NC) paid for competitor MRUS last fall, and our $1.5B peak sales forecast in 1L R/M HPV-negative HNSCC supports severalfold upside from current levels. We believe growing anticipation of the mid-2027 Phase 3 interim results could drive continued share appreciation."

For an analyst ratings summary and ratings history on Bicara Therapeutics Inc

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Thu, 03 Sep 2026 08:30:00 -0400

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on September 1, 2026 to two new employees as a material inducement to employment under Bicara’s 2026 Inducement Plan.

The employees received, in the aggregate, non-qualified stock options to purchase 380,575 shares of Bicara’s common stock, par value $0.0001 per share, inclusive of a non-qualified stock option to purchase 275,000 shares of Bicara’s common stock granted to the Company’s newly appointed Chief

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Thu, 03 Sep 2026 08:30:00 -0400

Form 8-K Bicara Therapeutics Inc. For: Aug 21

Tue, 25 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260825/26975520.html

Form 8-K Bicara Therapeutics Inc. For: Aug 21

Tue, 25 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260825/26975520.html

Bicara Therapeutics (BCAX) Reiterated at Market Outperform by Citizens as Pivotal Trial Advances

Fri, 21 Aug 2026 04:04:55 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $31.00 price target on Bicara Therapeutics Inc (NASDAQ: BCAX).

The analyst commented, "We reiterate our Market Outperform rating and price target of $31 for Bicara Therapeutics (BCAX), based on a discounted earnings per share and revenue multiple analysis. Recently, Bicara reported 2Q26 financial results and provided updates including management changes and milestones. With Bicara’s pivotal trial advancing rapidly, initial mCRC data expected in 2H26, and a cash position of $497.3MM, we believe Bicara shares represent an attractive investment opportunity, with ~55% potential downside (bear case $11) and ~93% potential upside (bull

BMO Capital Starts Bicara Therapeutics Inc (BCAX) at Outperform

Wed, 19 Aug 2026 05:30:06 -0400

(Updated - August 19, 2026 5:30 AM EDT)

BMO Capital analyst David Lebowitz initiates coverage on Bicara Therapeutics Inc (NASDAQ: BCAX) with a Outperform rating, PT$35.00.

The analyst comments "We are initiating coverage of Bicara Therapeutics with an Outperform rating and $35 target price. Bicara's bispecific, ficerafusp alfa, is a differentiated HNSCC asset with the potential to deliver broader, deeper, and more durable responses. The pivotal FORTIFI-HN01 interim analysis in mid-2027 is the key value inflection point, wherein a clear translation of strong Ph 1b activity indicates a strong market positioning, paving a path to accelerated approval in 2028 for a ~$2

BMO Capital Starts Bicara Therapeutics Inc (BCAX) at Outperform

Wed, 19 Aug 2026 05:30:06 -0400

(Updated - August 19, 2026 5:30 AM EDT)

BMO Capital analyst David Lebowitz initiates coverage on Bicara Therapeutics Inc (NASDAQ: BCAX) with a Outperform rating, PT$35.00.

Form 4 Bicara Therapeutics Inc. For: Aug 12 Filed by: Larson Jennifer

Fri, 14 Aug 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260814/26932282.html

Form 4 Bicara Therapeutics Inc. For: Aug 12 Filed by: Larson Jennifer

Fri, 14 Aug 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260814/26932282.html

Form 3 Bicara Therapeutics Inc. For: Aug 12 Filed by: Larson Jennifer

Fri, 14 Aug 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260814/26932269.html

Form 3 Bicara Therapeutics Inc. For: Aug 12 Filed by: Larson Jennifer

Fri, 14 Aug 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260814/26932269.html

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Fri, 14 Aug 2026 08:30:00 -0400

BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective August 12, 2026, it awarded an inducement grant to Jennifer Larson under Bicara’s 2026 Inducement Plan as a material inducement to her commencement of employment as Bicara’s Chief Financial Officer.

Ms. Larson received a non-qualified stock option to purchase 285,000 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $24.63 per share, equal to the closing price of

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Fri, 14 Aug 2026 08:30:00 -0400

Form SCHEDULE 13G/A Bicara Therapeutics Inc. Filed by: Janus Henderson Group Ltd.

Thu, 13 Aug 2026 12:42:00 -0400

si-local-file:///var/storage/secattach/20260813/26919217.html

Form SCHEDULE 13G/A Bicara Therapeutics Inc. Filed by: Janus Henderson Group Ltd.

Thu, 13 Aug 2026 12:42:00 -0400

si-local-file:///var/storage/secattach/20260813/26919217.html

Form 4 Bicara Therapeutics Inc. For: Aug 10 Filed by: Cohlhepp Ryan